Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 32236425

A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Neuro Oncol
Publication date
2020 Oct 14
First author
Ullrich NJ

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Neuro Oncol. 2020 Oct 14;22(10):1415-1416. doi: 10.1093/neuonc/noaa201.
    note
    Source null
    related pmid
    32974639
    relationship
    Comment in

Authors and identifiers

  1. name
    Ullrich NJ
    type
    Author
  2. name
    Prabhu SP
    type
    Author
  3. name
    Reddy AT
    type
    Author
  4. name
    Fisher MJ
    type
    Author
  5. name
    Packer R
    type
    Author
  6. name
    Goldman S
    type
    Author
  7. name
    Robison NJ
    type
    Author
  8. name
    Gutmann DH
    type
    Author
  9. name
    Viskochil DH
    type
    Author
  10. name
    Allen JC
    type
    Author
  11. name
    Korf B
    type
    Author
  12. name
    Cantor A
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Ullrich NJ
    type
    Author
  2. name
    Prabhu SP
    type
    Author
  3. name
    Reddy AT
    type
    Author
  4. name
    Fisher MJ
    type
    Author
  5. name
    Packer R
    type
    Author
  6. name
    Goldman S
    type
    Author
  7. name
    Robison NJ
    type
    Author
  8. name
    Gutmann DH
    type
    Author
  9. name
    Viskochil DH
    type
    Author
  10. name
    Allen JC
    type
    Author
  11. name
    Korf B
    type
    Author
  12. name
    Cantor A
    type
    Author
bibliography ids
  1. nci-bib-7423d2c4492fcb41f9a52f8a
book metadata
content sha256
3e2ab09cabdad19086990191c9ddde805918c3fccdb34678e80bc60d11d5bf71
document type
citation
dois
  1. 10.1093/neuonc/noaa071
electronic publication date
display
Source null
precision
missing
year
Source null
evidence scope
bibliographic_metadata_only
id
pubmed:32236425
immutable id
pubmed:32236425@3e2ab09cabdad19086990191c9ddde805918c3fccdb34678e80bc60d11d5bf71
journal
abbreviation
Neuro Oncol
issn electronic
1523-5866
issn print
1522-8517
issue
10
name
Neuro-oncology
nlm unique id
100887420
pages
1527-1535
volume
22
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Neuro Oncol. 2020 Oct 14;22(10):1415-1416. doi: 10.1093/neuonc/noaa201.
    note
    Source null
    related pmid
    32974639
    relationship
    Comment in
outcomes validated
false
pmid
32236425
provenance
batch id
40d9eae1f1d369f13109
provider
NCBI PubMed ESummary
record sha256
f4e4c33f4047d3c6a719ce6669bfe866d355b9e3abdb9f433e5a49027983a191
response sha256
03fa1567b6babd78281d8ec4529596b9d4953c2c4ac23257dca371d609645ba9
retrieved at
2026-09-09T23:47:52.637547+00:00
publication date
display
2020 Oct 14
precision
day
year
2020
publication types
  1. Clinical Trial, Phase II
  2. Journal Article
  3. Research Support, N.I.H., Extramural
  4. Research Support, U.S. Gov't, P.H.S.
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/32236425/
title
A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study.

Preserved source evidence · Not medical advice